ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
20 announcements with these filters
Dr. Reddy’s Laboratories will hold a board meeting on October 23, 2026, to approve the standalone and consolidated financial results for the quarter ending September 30, 2026.
Dr. Reddy's signed an exclusive distribution agreement with Takeda for Qdenga dengue vaccine in India's private market. No upfront consideration stated; availability expected H1 2027.
Dr. Reddy's confirmed a news report regarding a voluntary licensing agreement with Gilead Sciences for an HIV prevention drug, noting it is not material.
Dr. Reddy's Laboratories received two observations from the USFDA following a records assessment of its API manufacturing facility in Jiutepec, Mexico.
Dr. Reddy's Laboratories allotted 375 equity shares to employees upon the exercise of stock options under its ESOP scheme.
Dr. Reddy's Laboratories allotted 4,110 equity shares to employees under its 2002 Employee Stock Option Scheme. The shares rank pari passu with existing equity.
ICICI Prudential Mutual Fund acquired 7,12,884 shares of Dr. Reddy's Laboratories via the open market. This transaction increased the fund's total stake to 5.037%.
Dr. Reddy's Laboratories announced the resignation of Deepak Sapra, CEO of API and Services, effective November 12, 2026.
Dr. Reddy's Laboratories has terminated its distribution and promotion agreement with Novartis India Limited following a change in NIL's controlling shareholding.
Dr. Reddy's Laboratories received a Form 483 with three observations following a USFDA inspection at its Srikakulam FTO-SEZ unit, which the company will address.
Dr. Reddy's clarified a news report regarding Thailand's approval of its antibiotic NULZOLVENCE. The company confirmed the reports are correct and based on a joint press release.
Q1FY27 revenue fell 5.6% YoY to ₹8,071 Cr due to lower Lenalidomide sales. EBITDA margin at 12.5% (15.4% ex-one-offs) was hit by semaglutide API issues and Middle East conflict costs.
Dr. Reddy's Laboratories concluded its 42nd Annual General Meeting on July 23, 2026, with shareholders approving all agenda items, including a final dividend of ₹8 per share.
Q1FY27 revenues reached ₹8,071 Cr with 12.5% EBITDA margin. Results were significantly impacted by a ₹240 Cr semaglutide API charge; underlying EBITDA margin before this impact was 15.4%.
Dr. Reddy's Laboratories granted 15,933 stock options under its 2018 employee stock option scheme. The grant follows approval from the company's compensation committee.
Dr. Reddy's Laboratories appointed Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, and appointed Deloitte Haskins & Sells, LLP for US reporting.
Dr. Reddy's Laboratories Ltd reported revenue from operations of ₹8,100 Cr (-5.5% YoY) and net profit of ₹435.6 Cr (-69.1% YoY) for Q1 FY27.
Dr Reddys Laboratories Ltd filed its quarterly shareholding pattern as of June 30, 2026. The filing details holdings of promoters, institutions, and public shareholders.
Management discloses a significant manufacturing setback for Semaglutide injection due to out-of-specification impurity levels during scale-up, causing a temporary multi-month supply halt.
Dr. Reddy’s Laboratories disclosed that certain semaglutide batches are out of specification, causing a delay in commercial supplies. The company is investigating the issue.